Results 81 to 90 of about 259,058 (180)

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

open access: yesAndrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli   +7 more
wiley   +1 more source

Radiation therapy and androgen deprivation in the management of high risk prostate cancer

open access: yes, 2011
The combined use of radiation therapy (RT) and androgen deprivation for patients with localized high-risk prostate cancer is commonly accepted as the standard treatment among uro-oncologists.
Alan Dal Pra   +5 more
core   +1 more source

3D‐printed model for resection of positive surgical margins in robot‐assisted prostatectomy

open access: yesBJU International, Volume 135, Issue 4, Page 657-667, April 2025.
Objectives To improve precision of secondary resection (SR) after positive surgical margin (PSM) detection by frozen section (FS) during nerve‐sparing (NS) robot‐assisted radical prostatectomy (RARP) by employing a personalised three‐dimensional (3D)‐printed prostate model derived from pelvic magnetic resonance imaging (MRI).
Christian Engesser   +12 more
wiley   +1 more source

Androgen deprivation and immunotherapy for the treatment of prostate cancer

open access: yes, 2017
Prostate cancer is the most common newly diagnosed malignancy in men, and the second most common cause of cancer-related death in the United States.
Douglas G McNeel, Melissa Gamat
core   +1 more source

Long‐term oncological outcomes from a prospective cohort of patients with localised prostate cancer

open access: yesBJU International, EarlyView.
Objectives To report long‐term oncological outcomes for men with clinically localised prostate cancer (PCa) treated with contemporary modalities in a population‐based United States cohort. Patients and Methods The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study prospectively enrolled men with clinically localised PCa from ...
Avi S. Baskin   +17 more
wiley   +1 more source

Androgen deprivation therapy for prostate cancer

open access: yes, 2005
CONTEXT: Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in US men. Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced ...
Dahut, William L.   +2 more
core   +1 more source

Sexual function after prostate cancer surgery or radiotherapy in an international registry

open access: yesBJU International, EarlyView.
Objectives Our objective was to evaluate patient‐reported sexual function (SF) outcomes and sexual aid use 12 months after curative treatment for prostate cancer (PC). Patients & Methods This prospective registry‐based cohort study analysed men with localized or locally advanced PC enrolled in the TrueNTH Global Registry.
Y. Hess‐Busch   +10 more
wiley   +1 more source

Does Androgen Deprivation Therapy Impact Subjective Cognitive Function in Men with Non-metastatic Prostate Cancer? [PDF]

open access: yes, 2016
Androgen-deprivation therapy is used to treat almost 50% of current prostate cancer patients. Despite slowing disease progression and prolonging survival, androgen-deprivation therapy is associated with numerous side effects.
Marzouk, Shireen
core  

Androgen deprivation therapy toxicity and management for men receiving radiation therapy. Prostate Cancer 2012: 580306

open access: yes, 2012
Androgen deprivation therapy is commonly used in combination with radiotherapy as part of the definitive treatment for men with clinically localized and locally advanced prostate cancer.
Matthew E Johnson, Mark K Buyyounouski
core  

Comparative effectiveness of apalutamide‐, abiraterone‐, and enzalutamide‐based doublets in mHSPC

open access: yesBJU International, EarlyView.
Background and Objective Treatment of metastatic hormone‐sensitive prostate cancer (mHSPC) has evolved from androgen‐deprivation therapy (ADT) alone to combination therapy with androgen receptor pathway inhibitors. Although apalutamide (APA), abiraterone (ABI), and enzalutamide (ENZA) improve outcomes when added to ADT, direct comparative trials ...
Anikó Katalin Valikovics   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy